Florida Cancer Specialists Co-Authors 340B Reform Framework for Patient-Centered Oncology Care — Florida Cancer Specialists & Research Institute, LLC

Event summary

Florida Cancer Specialists' physician leaders Lucio N. Gordan, MD, and David Wenk, MD, co-authored a national commentary on 340B Drug Pricing Program reform, published in Evidence-Based Oncology on September 17, 2026.
The commentary proposes a patient-centered framework for 340B, emphasizing transparency, accountability, and measurable patient benefits in cancer care.
Key recommendations include patient-level eligibility standards, standardized public reporting, and tying eligibility to documented patient need rather than ownership structure.
The commentary will be featured on the cover of the October 2026 issue of Evidence-Based Oncology.

The big picture

The commentary reflects growing scrutiny of the 340B program's expansion and its implications for patient affordability and site-of-care trends. Florida Cancer Specialists' involvement underscores the strategic importance of value-based cancer care and the need for measurable patient benefits in policy decisions. The proposed framework could influence broader healthcare policy discussions on transparency and accountability in drug pricing programs.

What we're watching

Regulatory Impact: How proposed 340B reforms will affect patient affordability and practice consolidation in oncology.
Implementation Challenges: Whether the healthcare system can sustain the proposed transparency and accountability measures.
Site-of-Care Trends: The pace at which eligibility criteria shift from ownership structure to documented patient need.